Cost‐effectiveness analysis of dinutuximab β for the treatment of high‐risk neuroblastoma in China.Published in:Pediatric Blood & Cancer, 2023, v. 70, n. 12, p. 1, doi. 10.1002/pbc.30680By:Shen, An‐Le;Zhao, Jie;Yu, Li‐Ting;Zhang, An‐An;Wu, Bin;Fang, Ye;Han, Ya‐Li;Li, Chen‐Sui‐Zi;Li, Zhi‐Ling;Gao, Yi‐Jin;Zhang, Shun‐GuoPublication type:Article